These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 23696252

  • 1. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
    Sullivan-Chang L, O'Donnell RT, Tuscano JM.
    BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia.
    Kato J, Satake N, O'Donnell RT, Abuhay M, Lewis C, Tuscano JM.
    Leuk Res; 2013 Jan; 37(1):83-8. PubMed ID: 23040543
    [Abstract] [Full Text] [Related]

  • 3. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
    Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf IG, Schuler M, Sierra J, Smith MR, Verhoef G, Winter JN, Boni J, Vandendries E, Shapiro M, Fayad L.
    J Clin Oncol; 2010 Apr 20; 28(12):2085-93. PubMed ID: 20308665
    [Abstract] [Full Text] [Related]

  • 4. Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.
    Chang CH, Wang Y, Gupta P, Goldenberg DM.
    MAbs; 2015 Apr 20; 7(1):199-211. PubMed ID: 25484043
    [Abstract] [Full Text] [Related]

  • 5. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
    Shor B, Gerber HP, Sapra P.
    Mol Immunol; 2015 Oct 20; 67(2 Pt A):107-16. PubMed ID: 25304309
    [Abstract] [Full Text] [Related]

  • 6. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.
    Chevallier P, Eugene T, Robillard N, Isnard F, Nicolini F, Escoffre-Barbe M, Huguet F, Hunault M, Marcais A, Gaschet J, Cherel M, Guillaume T, Delaunay J, Peterlin P, Eveillard M, Thomas X, Ifrah N, Lapusan S, Bodet-Milin C, Barbet J, Faivre-Chauvet A, Ferrer L, Bene MC, Le Houerou C, Goldenberg DM, Wegener WA, Kraeber-Bodéré F.
    Lancet Haematol; 2015 Mar 20; 2(3):e108-17. PubMed ID: 26687796
    [Abstract] [Full Text] [Related]

  • 7. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
    DiJoseph JF, Popplewell A, Tickle S, Ladyman H, Lawson A, Kunz A, Khandke K, Armellino DC, Boghaert ER, Hamann P, Zinkewich-Peotti K, Stephens S, Weir N, Damle NK.
    Cancer Immunol Immunother; 2005 Jan 20; 54(1):11-24. PubMed ID: 15693135
    [Abstract] [Full Text] [Related]

  • 8. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
    Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJ, Pastan I.
    Clin Cancer Res; 2000 Apr 20; 6(4):1476-87. PubMed ID: 10778980
    [Abstract] [Full Text] [Related]

  • 9. Moxetumomab Pasudotox: First Global Approval.
    Dhillon S.
    Drugs; 2018 Nov 20; 78(16):1763-1767. PubMed ID: 30357593
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
    Kreitman RJ, Pastan I.
    Clin Cancer Res; 2011 Oct 15; 17(20):6398-405. PubMed ID: 22003067
    [Abstract] [Full Text] [Related]

  • 12. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
    Choudhry A, O'Brien SM.
    Drugs Today (Barc); 2017 Dec 15; 53(12):653-665. PubMed ID: 29517084
    [Abstract] [Full Text] [Related]

  • 13. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia.
    Litzow MR.
    Am Soc Clin Oncol Educ Book; 2013 Dec 15; ():294-9. PubMed ID: 23714527
    [Abstract] [Full Text] [Related]

  • 14. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
    Farhadfar N, Litzow MR.
    Leuk Res; 2016 Oct 15; 49():13-21. PubMed ID: 27521873
    [Abstract] [Full Text] [Related]

  • 15. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
    DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C, Moran JK, Popplewell AG, Stephens S, Frost P, Damle NK.
    Blood; 2004 Mar 01; 103(5):1807-14. PubMed ID: 14615373
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas.
    Ohanian M, Kantarjian H, Guy D, Thomas D, Jabbour E, O'Brien S.
    Expert Opin Biol Ther; 2015 Apr 01; 15(4):601-11. PubMed ID: 25775418
    [Abstract] [Full Text] [Related]

  • 18. Inotuzumab Ozogamicin: First Global Approval.
    Lamb YN.
    Drugs; 2017 Sep 01; 77(14):1603-1610. PubMed ID: 28819740
    [Abstract] [Full Text] [Related]

  • 19. BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle.
    Chevallier P, Bodet-Milin C, Robillard N, Eugene T, Menard A, Le Houerou C, Guillaume T, Delaunay J, Escoffre-Barbe M, Wegener WA, Goldenberg DM, Kraeber-Bodéré F.
    Eur J Haematol; 2013 Dec 01; 91(6):552-6. PubMed ID: 23927500
    [Abstract] [Full Text] [Related]

  • 20. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.
    Leonard JP, Goldenberg DM.
    Oncogene; 2007 May 28; 26(25):3704-13. PubMed ID: 17530024
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.